The modern practice of waiting for detailed diagnostic and genetic information before starting AML therapy provides a crucial, previously unavailable window of time for clinicians to conduct thorough fitness and geriatric assessments on their older patients.

When treating elderly patients (e.g., age 80+) with metastatic breast cancer, clinicians may prioritize quality of life over marginal overall survival gains seen in clinical trials. This justifies using a better-tolerated CDK4/6 inhibitor like palbociclib, even though ribociclib has demonstrated a statistical survival benefit, especially when patients have comorbidities or a preference for fewer side effects.

While cosmetic results are a significant consideration in modern breast surgery, the primary, non-negotiable goal is eradicating the cancer to prevent recurrence. Surgeons emphasize that aesthetic goals, while a 'very close second,' must not compromise the thoroughness of the cancer treatment, a crucial distinction for patients and providers.

Unlike many other breast cancer gene mutations, TP53 carriers are extremely sensitive to radiation. Standard radiation therapy following a lumpectomy can induce a high risk of developing fatal sarcomas. For these specific patients, mastectomy is a safer surgical approach to avoid radiation exposure.

For BRCA mutation carriers without cancer, the choice is not just about survival. While prophylactic mastectomy prevents most cancers, intensive screening with mammography and MRI detects cancers early enough that mortality rates are not significantly different. This allows patients to choose based on personal risk tolerance.

A nuanced approach to PARP inhibitors involves reserving combinations for BRCA2 patients with clear, aggressive clinical features like high-volume disease or liver metastases. This strategy balances potent efficacy against toxicity for a molecularly defined but clinically heterogeneous group, avoiding overtreatment of those with more indolent disease.

Modern breast cancer treatment has shifted from a 'one-size-fits-all' aggressive approach to a highly individualized one. By de-escalating care—doing smaller surgeries, minimizing radiation, and sometimes omitting chemotherapy or lymph node biopsies—clinicians can achieve better outcomes with fewer long-term complications for patients with favorable disease characteristics.

The high efficacy of neoadjuvant TDXD in high-risk HER2+ breast cancer presents a compelling argument to avoid initial surgery for patients with reasonably sized tumors. There is currently no data to support using adjuvant TDXD for patients who undergo surgery first.

Giving adjuvant olaparib to BRCA-mutated patients who have already achieved a pathologic complete response (pCR) from neoadjuvant platinum-based chemotherapy is discouraged. Their prognosis is already excellent, so adding a PARP inhibitor offers little potential benefit while exposing them to unnecessary risks of toxicity, such as MDS/AML.